Method of treating immunoglobulin light chain amyloidosis
The present invention relates to the use of substituted quinoline compounds for treating immunoglobulin light chain (LC) amyloidosis (AL), especially cardiotoxicity associated with immunoglobulin LC AL. In particular, the substituted quinoline compounds useful in the treatment of cardiac LC amyloidosis are 5,7-dihalo-8-hydroxyquinoline derivatives, especially 5,7-dichloro-8-hydroxyquinoline derivatives.
1. A method of treating immunoglobulin light chain amyloidosis in a subject in need thereof comprising administering a compound of formula (I):
wherein
R, R 1 and R 3 are the same or different and are each independently selected from hydrogen, —C 1-3 alkyl, —C 2-3 alkenyl, —C 2-3 alkynyl, —CF 3 , —CHF 2 , —CH 2 F, —CH 2 CF 3 , —CH 2 CF 2 H, —CH 2 CH 2 F, —OH, —OC 1-6 alkyl, —OCF 3 , —OCHF 2 , —OCH 2 F, —OCH 2 CF 3 , —OCH 2 CHF 2 , —OCH 2 CH 2 F, —OC 2-3 alkenyl, —OC 2-3 alkynyl, —NH 2 , —NH(C 1-3 alkyl), —N(C 1-3 alkyl) 2 , —SO 2 C 1-6 alkyl, —CO 2 H, —CO 2 C 1-3 alkyl, —CONH 2 , —CONH(C 1-3 alkyl), —CON(C 1-3 alkyl) 2 , F, Cl and Br;
R 2 is selected from —(CH 2 ) m heterocyclyl, —(CH 2 ) m C(O)R 9 , —(CH 2 ) m CN, —(CH 2 ) m NR 7 R 8 , —CH═NC 1-6 alkyl, —CH═N—OR 6 , —CH═N—NR 10 R 11 , —SO 2 NR 10 R 11 and —(CH 2 ) m OR 6 ;
R 4 and R 5 are the same or different and are independently selected from F, Cl and I;
R 6 is selected from hydrogen, —C 1-6 alkyl, —C 2-6 alkenyl, —C 2-6 alkynyl, —C 1-6 haloalkyl, aryl and heteroaryl;
R 7 and R 8 are the same or different and are independently selected from hydrogen, —C 1-6 alkyl, —C 2-6 alkenyl, —C 2-6 alkynyl, —C 1-6 haloalkyl, —(CH 2 ) m aryl and —(CH 2 ) m heterocyclyl, or R 7 and R 8 taken together form a heterocyclic ring;
R 9 is selected from hydrogen, —C 1-6 alkyl, —C 2-6 alkenyl, —C 2-6 alkynyl, —C 1-6 haloalkyl, —OR 6 , —SR 6 , —NR 7 R 8 , aryl and heteroaryl;
R 10 and R 11 are the same or different and are independently selected from hydrogen, —C 1-6 alkyl, —C 2-6 alkenyl, —C 2-6 alkynyl, —C 1-6 haloalkyl, aryl and heteroaryl;
m is 0 or 1;
wherein each alkyl, alkenyl, alkynyl, aryl and heteroaryl group may be optionally substituted;
or a pharmaceutically acceptable salt, hydrate or solvate thereof.
2. The method according to claim 1 wherein the method alleviates or reverses the symptoms of immunoglobulin light chain amyloidosis.
3. The method according to claim 1 wherein the immunoglobulin light chain amyloidosis is cardiac immunoglobulin light chain amyloidosis.
4. A method of treating or alleviating or reversing the symptoms of cardiotoxicity associated with immunoglobulin light chain amyloidosis in a subject in need thereof comprising administering a compound of formula (I):
wherein
R, R 1 and R 3 are the same or different and are each independently selected from hydrogen, —C 1-3 alkyl, —C 2-3 alkenyl, —C 2-3 alkynyl, —CF 3 , —CHF 2 , —CH 2 F, —CH 2 CF 3 , —CH 2 CF 2 H, —CH 2 CH 2 F, —OH, —OC 1-6 alkyl, —OCF 3 , —OCHF 2 , —OCH 2 F, —OCH 2 CF 3 , —OCH 2 CHF 2 , —OCH 2 CH 2 F, —OC 2-3 alkenyl, —OC 2-3 alkynyl, —NH 2 , —NH(C 1-3 alkyl), —N(C 1-3 alkyl) 2 , —SO 2 C 1-6 alkyl, —CO 2 H, —CO 2 C 1-3 alkyl, —CONH 2 , —CONH(C 1-3 alkyl), —CON(C 1-3 alkyl) 2 , F, Cl and Br;
R 2 is selected from —(CH 2 ) m heterocyclyl, —(CH 2 ) m C(O)R 9 , —(CH 2 ) m CN, —(CH 2 ) m NR 7 R 8 , —CH═NC 1-6 alkyl, —CH═N—OR 6 , —CH═N—NR 10 R 11 , —SO 2 NR 10 R 11 and —(CH 2 ) m OR 6 ;
R 4 and R 5 are the same or different and are independently selected from F, Cl and I;
R 6 is selected from hydrogen, —C 1-6 alkyl, —C 2-6 alkenyl, —C 2-6 alkynyl, —C 1-6 haloalkyl, aryl and heteroaryl;
R 7 and R 8 are the same or different and are independently selected from hydrogen, —C 1-6 alkyl, —C 2-6 alkenyl, —C 2-6 alkynyl, —C 1-6 haloalkyl, —(CH 2 ) m aryl and —(CH 2 ) m heterocyclyl, or R 7 and R 8 taken together form a heterocyclic ring;
R 9 is selected from hydrogen, —C 1-6 alkyl, —C 2-6 alkenyl, —C 2-6 alkynyl, —C 1-6 haloalkyl, —OR 6 , —SR 6 , —NR 7 R 8 , aryl and heteroaryl;
R 10 and R 11 are the same or different and are independently selected from hydrogen, —C 1-6 alkyl, —C 2-6 alkenyl, —C 2-6 alkynyl, —C 1-6 haloalkyl, aryl and heteroaryl;
m is 0 or 1;
wherein each alkyl, alkenyl, alkynyl, aryl and heteroaryl group may be optionally substituted;
or a pharmaceutically acceptable salt, hydrate or solvate thereof.
5. The method according to claim 4 wherein the method is for reversing the damage caused by cardiotoxic immunoglobulin light chains deposited in heart tissue.
6. The method according to claim 1 wherein R, R 1 and R 3 are all hydrogen.
7. The method according to claim 1 wherein R 2 is selected from heterocyclyl, —CH 2 heterocyclyl, —CO 2 H, —C(O)NR 7 R 8 , —NR 7 R 8 , —CH 2 NR 7 R 8 , —CH═NOH, —CH═NOC 1-6 alkyl, —CH 2 OR 6 or —SO 2 NR 10 R 11 .
8. The method according to claim 7 wherein R 2 is selected from —C(O)NH(CH 2 heterocyclyl), —C(O)NH(CH 2 CH 2 heterocyclyl), pyridyl, —CH 2 N(C 1-3 alkyl) 2 , —N(C 1-3 alkyl)(heterocyclyl), —CH 2 NH(C 1-3 alkyl), —CH═N—OH, —CH═N—OCH 3 , —CH 2 OC 1-6 alkyl, —CH 2 OC 1-6 haloalkyl, —CH═NCH 3 and —CH 2 N(C 1-3 alkyl)(CH 2 heterocyclyl).
9. A method according to claim 1 wherein R 4 and R 5 are both Cl.
10. The method according to claim 1 wherein the compound of formula (I) is selected from:
where n is 1, 2 or 3.
11. The method according to claim 1 further comprising administration of another pharmaceutically active agent.
12. The method according to claim 11 wherein the other pharmaceutically active agent is an antioxidant or a pharmaceutically active agent for treating immunoglobulin light chain amyloidosis.
13. A method of treating or alleviating or reversing the symptoms of immunoglobulin light chain amyloidosis comprising administering to a subject in need thereof an effective amount of a compound of formula (I)
wherein
R, R 1 and R 3 are the same or different and are each independently selected from hydrogen, —C 1-3 alkyl, —C 2-3 alkenyl, —C 2-3 alkynyl, —CF 3 , —CHF 2 , —CH 2 F, —CH 2 CF 3 , —CH 2 CF 2 H, —CH 2 CH 2 F, —OH, —OC 1-6 alkyl, —OCF 3 , —OCHF 2 , —OCH 2 F, —OCH 2 CF 3 , —OCH 2 CHF 2 , —OCH 2 CH 2 F, —OC 2-3 alkenyl, —OC 2-3 alkynyl, —NH 2 , —NH(C 1-3 alkyl), —N(C 1-3 alkyl) 2 , —SO 2 C 1-6 alkyl, —CO 2 H, —CO 2 C 1-3 alkyl, —CONH 2 , —CONH(C 1-3 alkyl), —CON(C 1-3 alkyl) 2 , F, Cl and Br;
R 2 is selected from —(CH 2 ) m heterocyclyl, —(CH 2 ) m C(O)R 9 , —(CH 2 ) m CN, —(CH 2 ) m NR 7 R 8 , —CH═NC 1-6 alkyl, —CH═N—OR 6 , —CH═N—NR 10 R 11 , —SO 2 NR 10 R 11 and —(CH 2 ) m OR 6 ;
R 4 and R 5 are the same or different and are independently selected from F, Cl and I;
R 6 is selected from hydrogen, —C 1-6 alkyl, —C 2-6 alkenyl, —C 2-6 alkynyl, —C 1-6 haloalkyl, aryl and heteroaryl;
R 7 and R 8 are the same or different and are independently selected from hydrogen, —C 1-6 alkyl, —C 2-6 alkenyl, —C 2-6 alkynyl, —C 1-6 haloalkyl, —(CH 2 ) m aryl and —(CH 2 ) m heterocyclyl, or R 7 and R 8 taken together form a heterocyclic ring;
R 9 is selected from hydrogen, —C 1-6 alkyl, —C 2-6 alkenyl, —C 2-6 alkynyl, —C 1-6 haloalkyl, —OR 6 , —SR 6 , —NR 7 R 8 , aryl and heteroaryl;
R 10 and R 11 are the same or different and are independently selected from hydrogen, —C 1-6 alkyl, —C 2-6 alkenyl, —C 2-6 alkynyl, —C 1-6 haloalkyl, aryl and heteroaryl;
m is 0 or 1;
wherein each alkyl, alkenyl, alkynyl, aryl and heteroaryl group may be optionally substituted; or a pharmaceutically acceptable salt, hydrate or solvate thereof; and an effective amount of an antioxidant.
14. The method according to claim 13 wherein the symptoms treated, alleviated or reversed are associated with cardiotoxic immunoglobulin light chain deposits in heart tissue.
15. The method according to claim 13 wherein the effective amount of the compound of formula (I) is a sub-therapeutic amount.
16. The method according to claim 13 wherein the compound of formula (I) is
17. The method according to claim 13 wherein the antioxidant is tetracycline.